Fred Hassan
CIK 1110744 · Chairman and CEO · last filed 2026-06-24
Fred Hassan is a Chairman and CEO who has filed 86 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for BBIO, was dated Jun 24, 2026. Across all open-market trades the lifetime net is +$5.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $15.0M across reported positions. 25 SEC filings were submitted jointly with TIME WARNER INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MRK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1100 HOLLAND DR.
BOCA RATON, FL 33487
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BBIO | Director | 29,879 | $68.15 | $2.04M | $273.4K | 7 | 2026-06-24 |
| PGEN | Director | 1,243,239 | $6.04 | $7.51M | $998.1K | 14 | 2026-03-16 |
| COCP | Director | 1,383,009 | $0.97 | $1.34M | $0 | 4 | 2026-01-13 |
| EYPT | Director | — | $0.37 | — | $0 | 3 | 2026-01-06 |
| Prometheus Biosciences, Inc. (RXDX) Delisted | Director | 0 | $199.92 | $0 | $0 | 5 | 2023-06-16 |
| AMGN | Director | 9,191 | $444.63 | $4.09M | $501.6K | 7 | 2020-05-07 |
| PRECIGEN, INC. (XON) Delisted | Director | 32,358 | — | — | $200.3K | 6 | 2019-03-26 |
| WARNER MEDIA, LLC (TWX) Delisted | Director | 0 | — | — | $1.01M | 22 | 2018-06-18 |
| AVON PRODUCTS INC (AVP) Delisted | Director | 49,079 | — | — | $0 | 8 | 2012-05-07 |
| MRK | Chairman and CEO | 0 | $140.61 | $0 | $2.01M | 8 | 2009-11-04 |
Recent Filings
86 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-24 | BBIO | Grant (A) | +3,990 | $0 | EDGAR |
| 2026-03-16 | PGEN | Exer (M) | +71,839 | $0 | EDGAR |
| 2026-03-12 | PGEN | Grant (A) | +17,948 | $63.0K | EDGAR |
| 2026-01-13 | COCP | Grant (A) | — | $0 | EDGAR |
| 2026-01-06 | EYPT | Grant (A) | — | $0 | EDGAR |
| 2025-10-30 | COCP | Grant (A) | +359,713 | $500.0K | EDGAR |
| 2025-06-24 | BBIO | Grant (A) | +6,589 | $0 | EDGAR |
| 2025-03-17 | PGEN | Mixed | +123,618 | $63.0K | EDGAR |
| 2025-01-07 | EYPT | Grant (A) | — | $0 | EDGAR |
| 2024-10-11 | COCP | Grant (A) | +8,067 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.